Athira Pharma (ATHA) Stock Price, News & Analysis

Company Overview

Athira Pharma, Inc. is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system. Fosgonimeton has advanced through Phase 1 and Phase 2 clinical trials, where it has been evaluated for safety, tolerability and preliminary efficacy in patients with mild to moderate Alzheimer’s disease and other forms of cognitive impairment. In addition to ATH‐1017, the company is exploring follow‐on small‐molecule candidates designed to target related pathways and broaden the potential therapeutic impact across multiple neurodegenerative indications.

Athira Pharma went public in 2019 and is traded on the Nasdaq under the symbol ATHA. The company conducts clinical studies in the United States and Europe in collaboration with academic research centers and contract research organizations. Leadership has included key figures from both the biotech and neuroscience research communities, with a management team experienced in drug development, clinical operations and regulatory affairs. Athira continues to engage with strategic partners to support its mission of bringing novel, disease‐modifying treatments to patients suffering from progressive neurological disorders.

Key Stats

• Today's Range: $8.78 to $9.62
• 50-Day Range: $5.30 to $11.68
• 52-Week Range: $0.23 to $8.36
• Volume: 25,155 shs
• Average Volume: 602,475 shs
• Market Capitalization: $37.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Sell

Athira Pharma Stock Analysis - MarketRank™

Athira Pharma scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Athira Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Downside Risk

Athira Pharma has a consensus price target of $4.00, representing about 58.1% downside from its current price of $9.55.

Amount of Analyst Coverage

Athira Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Athira Pharma are expected to grow in the coming year, from ($2.35) to ($0.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Athira Pharma is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Athira Pharma is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Athira Pharma has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ATHA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Athira Pharma does not currently pay a dividend.

Dividend Growth

Athira Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Athira Pharma this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Athira Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.80% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATHA Stock Analysis - Frequently Asked Questions

How have ATHA shares performed this year?

Athira Pharma's stock was trading at $7.57 at the start of the year. Since then, ATHA stock has increased by 26.2% and is now trading at $9.55.

How were Athira Pharma's earnings last quarter?

Athira Pharma, Inc. (NASDAQ:ATHA) released its quarterly earnings data on Thursday, November, 6th. The company reported ($1.68) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $1.51.

When did Athira Pharma's stock split?

Athira Pharma shares reverse split on Thursday, September 18th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Athira Pharma IPO?

Athira Pharma (ATHA) raised $192 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 12,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager.

How do I buy shares of Athira Pharma?

Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Athira Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include Pfizer (PFE), PayPal (PYPL), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/06/2025
• Today: 5/06/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATHA
• CIK: 1620463
• Web: athira.com
• Phone: 425-620-8501
• Fax: N/A
• Employees: 40
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Athira Pharma: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: -58.1%
• Consensus Rating: Sell
• Rating Score (0-4): 1.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$96.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -107.06%
• Return on Assets: -89.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.70
• Quick Ratio: 9.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.60 per share
• Price / Book: 0.82

Miscellaneous

• Outstanding Shares: 3,944,000
• Free Float: 3,163,000
• Market Cap: $37.67 million
• Optionable: No Data
• Beta: 2.79